Idexx Laboratories, Inc. (IDXX) Tops Q2 EPS by 11c; Boosts FY11 EPS Outlook
Idexx Laboratories, Inc. (NASDAQ: IDXX) reported Q2 EPS of $0.83, $0.11 better than the analyst estimate of $0.72. Revenue for the quarter came in at $317.9 million versus the consensus estimate of $308.58 million.
Idexx Laboratories, Inc. sees FY2011 EPS of $2.68-$2.73, versus prior guidance of $2.66-$2.71 and the consensus of $2.70. Idexx Laboratories, Inc. sees FY2011 revenue of $1.205-$1.215 billion, versus the consensus of $1.21 billion.
Idexx Laboratories, Inc. sees FY2011 EPS of $2.68-$2.73, versus prior guidance of $2.66-$2.71 and the consensus of $2.70. Idexx Laboratories, Inc. sees FY2011 revenue of $1.205-$1.215 billion, versus the consensus of $1.21 billion.